Structure of 138377-80-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 138377-80-7 |
Formula : | C5H11ClN2O |
M.W : | 150.61 |
SMILES Code : | O=C1NCCCC1N.[H]Cl |
MDL No. : | MFCD09028970 |
InChI Key : | NLAYLURYAOXTTE-UHFFFAOYSA-N |
Pubchem ID : | 19795138 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Num. heavy atoms | 9 |
Num. arom. heavy atoms | 0 |
Fraction Csp3 | 0.8 |
Num. rotatable bonds | 0 |
Num. H-bond acceptors | 2.0 |
Num. H-bond donors | 2.0 |
Molar Refractivity | 40.62 |
TPSA ? Topological Polar Surface Area: Calculated from |
55.12 Ų |
Log Po/w (iLOGP)? iLOGP: in-house physics-based method implemented from |
0.0 |
Log Po/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by |
-0.05 |
Log Po/w (WLOGP)? WLOGP: Atomistic method implemented from |
-0.36 |
Log Po/w (MLOGP)? MLOGP: Topological method implemented from |
-0.41 |
Log Po/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by |
0.13 |
Consensus Log Po/w? Consensus Log Po/w: Average of all five predictions |
-0.14 |
Log S (ESOL):? ESOL: Topological method implemented from |
-0.74 |
Solubility | 27.3 mg/ml ; 0.181 mol/l |
Class? Solubility class: Log S scale |
Very soluble |
Log S (Ali)? Ali: Topological method implemented from |
-0.66 |
Solubility | 33.2 mg/ml ; 0.22 mol/l |
Class? Solubility class: Log S scale |
Very soluble |
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by |
-0.56 |
Solubility | 41.3 mg/ml ; 0.274 mol/l |
Class? Solubility class: Log S scale |
Soluble |
GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg |
High |
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg |
No |
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) |
No |
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) |
No |
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) |
No |
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) |
No |
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) |
No |
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) |
No |
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from |
-7.25 cm/s |
Lipinski? Lipinski (Pfizer) filter: implemented from |
0.0 |
Ghose? Ghose filter: implemented from |
None |
Veber? Veber (GSK) filter: implemented from |
0.0 |
Egan? Egan (Pharmacia) filter: implemented from |
0.0 |
Muegge? Muegge (Bayer) filter: implemented from |
1.0 |
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat |
0.55 |
PAINS? Pan Assay Interference Structures: implemented from |
0.0 alert |
Brenk? Structural Alert: implemented from |
0.0 alert: heavy_metal |
Leadlikeness? Leadlikeness: implemented from |
No; 1 violation:MW<1.0 |
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) |
1.57 |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
83% | With sodium 2-ethylhexanoic acid; In tetrahydrofuran; at 20℃; for 96h; | 24.64 mg of 4 (0.087 mmol), 41.05 mg of sodium 2-ethyl-hexanoate (0.247 mmol), 20.16 mg of 15 (which may be prepared according to the procedures described in WO 2002/081480, and the content of which is incorporated herein by reference) (0.134 mmol) and 2 ml of THF are successively introduced into a 20 ml round-bottomed flask with stirring and under an argon atmosphere. Stirring is continued for 4 days at r.t. 20 ml of EtOAc are added to the reaction medium, which is then washed successively with 20 ml of NaOH solution (0.1 N), 20 ml of water and 20 ml of saturated NaCl solution. As product has visibly dissolved in the aqueous phase, this aqueous phase is extracted twice with a mixture of 50 ml of CH2Cl2 and 5 ml of MeOH. The 3 organic phases are combined, dried, filtered and then evaporated to dryness. The crude product is purified by PCC with a 93/7 CH2Cl2/MeOH mixture. 28.49 mg of product 16 are collected (Yld=83percent). TLC (90/10 CH2Cl2/MeOH): Rf=0.28 1H NMR (400 MHz, CDCl3): delta (ppm)=7.11 (d, 1H); 5.70 (d, 1H); 5.67 (m, 1H); 5.48 (dd, 1H); 4.72 (m, 1H); 4.20 (d, 1H); 4.02 (d, 1H); 3.80 (d, 1H); 3.50 (s, 1H); 3.49 (s, 3H); 3.36 (m, 2H); 2.54 (m, 2H); 1.96 (m, 2H); 1.47 (s, 6H); 1.02 (s, 9H) LCMS (ES+, 30 V): tR=2.92 mn|m/z=797+ (2M+H+); 399+ (M+H+); 341+ (M+H+[(H3C)2CO]); 841 (2 MH+HCOOH); 443 (MH+HCOOH) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
20% | With N-ethyl-N,N-diisopropylamine; HATU; In DMF (N,N-dimethyl-formamide); at 0 - 20℃; for 3h; | [Preparation Example 116] Preparation of 3-[(benzylsulfonyl)(methyl)amino]-N-((1S,2S,4R)-2-[tert- butyl(dimethyl)silyl]oxy}-1-isobutyl-4-methyl-5-oxo-5-[(3R or 3S)-2- OXOPIPERIDINYL] AMMO} PENTVBENZAMIDE 91 mg (0. 15 mmol) of the compound obtained in Preparation Example 58 was dissolved in 5 ml of N, N-DIMETHYLFORMAMIDE and cooled to 0°C, then 34 mg (0.225 mmol) obtained in Preparation Example 115 and 86 mg (0.225 mmol) of HATU were added thereto. 0.5 ml (excess amount) of N, N-diisopropylethylamine was then added thereto and heated to room temperature, followed by stirring for 3 hours. After removing solvent by distillation under reduced pressure, the residue was dissolved in ethyl acetate and washed with water, 0.5 N hydrochloride solution, saturated sodium bicarbonate solution and sodium chloride solution. After removing solvent by distillation under reduced pressure, the product was purified by column chromatography using a 5: 95 mixture of methanol and dichloromethane to obtain 21 mg of the title compound at 20percent yield. 1H NMR (400 MHz, CDC) ; 7.82 (1H, s), 7.59 (1H, d), 7.45-7. 33 (7H, m), 6.79 (1H, d), 6.27 (1H, d), 5.48 (1H, s), 4.50-4. 20 (4H, m), 3.80 (1H, m), 3.23 (3H, s), 3.22-3. 12 (2H, m), 2.54 (1H, m), 2.28 (1H, m), 1.97 (1H, m), 1.92-1. 48 (6H, m), 1.39 (1H, m), 1.17 (3H, d), 0.98 (3H, d), 0.97 (3H, d), 0.91 (9H, s), 0.12 (3H, s), 0.11 (3H, s) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Example 10 ; 3-[({4-[(3-chloro-2-fluorophenyl) amino]-7-methoxyquinazolin-6- yl} methyl) amino] piperidin-2-one; (Process (a)); 4- [ (3-Chloro-2-fluorophenyl) amino]-7-methoxyquinazoline-6-carbaldehyde was coupled with 3-amino-piperidin-2-one (prepared by converting <strong>[138377-80-7]3-amino-piperidin-2-one hydrochloride</strong> to the free-base form) using an analogous method to that described for the equivalent step in Example 1 to give the title compound ; 1H NMR spectrum : (DMSO d6) 1. 5= (m, 1H), 1.68 (m, 1H), 1.84 (m, 1H), 2.16 (m, 1H), 2.73 (brs, 1H), 3.05 (dd, 1H), 3.13 (m, 2H), 3.84 (d, 1H), 3.93 (d, 1H), 3.98 (s, 3H), 7.21 (s, 1H), 7.28 (t, 1H), 7.48 (t, 1H), 7.53 (m, 2H), 8.35 (s, 1H), 8.44 (s, 1H), 9.80 (s, 1H); Mass Spectrum : (M+H) +430. | ||
With AMBERLYST A21; In methanol; at 20℃; | To a solution of <strong>[138377-80-7]3-aminopiperidin-2-one hydrochloride</strong> (1.50 g) in methanol (10 mL) was added AMBERLYST (registered trademark) A21 (750 mg) at room temperature. The reaction mixture was stirred at room temperature overnight, theinsoluble material was removed by filtration, and the filtrate was concentrated under reduced pressure. To a solution of the residue in ethanol (20 mL) was added 4-thioxothiazolidin-2-one (1.330 g) at room temperature. The reaction mixture wasstirred at room temperature overnight, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (NH, methanol/ethyl acetate) . To a solution of the residue and l-[2,4- bis (trifluoromethyl) benzyl] piperidine-4-carbaldehyde (1018 mg) in 2-propanol (10 mL) was added piperidinium acetate (436 mg) at room temperature. The reaction mixture was stirred at 60°C overnight, and the solvent was evaporated under reducedpressure. The residue was purified by silica gel columnchromatography (NH, methanol/ethyl acetate) and recrystallized from ethyl acetate/diisopropyl ether to give the titlecompound (530 mg) .¾ NMR (300 MHz, DMSO-d6) delta 1.38-1.59 (2H, m) , 1.68-1.91 (5H, m) , 2.01-2.27 (4H, m) , 2.69-2.84 (2H, m) , 3.17 (2H, brs) , 3.71 (2H, s), 4.43-4.55 (1H, m) , 6.89 (1H, d, J = 8.8 Hz), 7.83 (1H, brs), 7.98 (1H, s) , 8.02-8.12 (2H, m) , 9.34 (1H, brs).MS (ESI+) : [M+H]+ 535.1. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
77% | With triethylamine; In tetrahydrofuran; at 80℃; for 24h; | Phenyl {3-[(2-aminopyrimidin-5-yl) ethynyl] phenyl} carbamate (Example 23) (50 mg), 3- amino-piperidin-2-one hydrochloride (46 mg) and triethylamine (0.06 mL) in THF (2 mL) were heated at 80°C for 24 hours. The reaction mixture was concentrated in vacuo and the solid triturated with water then diethyl ether, dried under vacuum at 60°C to give the title compound as a beige solid (41 mg, 77percent) ; 'H NMR (DMSO-d6) 1.49-1. 62 (m, 1H), 1.71-1. 82 (m, 2H), 2.16-2. 28 (m, 1H), 3.10-3. 18 (m, 2H), 3.95-4. 04 (m, 1H), 6.42-6. 48 (d, 2H), 6.98-7. 04 (m, 1H), 7.09 (s, 2H), 7.20-7. 31 (m, 2H), 7.65 (s, 2H), 8.41 (s, 2H), 8.85 (s, 1H) ; MS m/e MH 351. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
69% | With potassium carbonate; | Reference Example 1 : 3-(4,-MethylbenzenesuIfonylamino)tetrahydropyridin-2- one:; <strong>[138377-80-7]3-aminotetrahydropyridin-2-one hydrochloride</strong> (10 mmol), K2C03 (30 mmol) and 4- methylbenzenesulfonyl chloride (10 mmol) were reacted according to the above procedure to give the product (1.64 g, 69percent):Vmax/cm"1 3224, 1658 (secondary CONH, lactam), 1598, 1494 (aromatic ring), 1324, 1161 (S02-N), 814, 802 (pam-disubstituted benzene). NMR: deltaEta (400MHz, CDC13) 7.77 (2H, d, J 8.5, ortho-U), 7.29 (2H, d, J 8.0, meta- H), 5.79 (1H, br d, J 1.0, C7H7-S02NH), 5.56 (1Eta, br s, CONH-CH2), 3.49-3.42 (1H, m, CH-CO), 3.31-3.24 (2H, m, CH2NH), 2.53-2.45 (1H, m, lactam CH2), 2.40 (3H, s, CH3), 1.97-1.88 (1H, m, lactam CH2), 1.88-1.68 (2H, m, lactam CH2). 13C NMR: 6C (100MHz, CDC13) 172.2 (lactam C=0), 142.2 (ipso-C), 136.2 (para-C), 129.7 (aromatic CH), 127.3 (aromatic CH), 53.3 (CH-CO), 42.0 (C3/4-NH), 29.6 (lactam CH2), 28.6 (lactam CH2), 27.9 (lactam CH2), 21.5 (CH3).HRMS (+ESI) C,2H16N203S + Na+: calcd 291.0774; found 291.0777. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With potassium carbonate; In dichloromethane; water; | Reference Example 11 : 3-(Pyridin-3'-carbonylamino)tetrahydropyridin-2- one:; Oxalyl chloride (20 mmol) was added to a solution of nicotinic acid (10 mmol) in DCM (40 mL), along with one drop of catalytic DMF. The reaction mixture was stirred for 16 h and then the solvent was removed under high vacuum. The resulting crystals were dissolved in DCM (10 mL). In a separate flask, 3- aminotetrahydropyridin-2-one hydrochloride (10 mmol) and 2C03 (30 mmol) were added to water (30 mL) and stirred, giving a solution to which the acid chloride solution was added. The reaction was worked-up as above to give the product (0.10 g, 5percent):Vmax cm"' 3257 (N-H, amide), 1642, 1541 (secondary CONH, lactam, NH), 1591 , 1479 (aromatic pyridine ring). NMR: deltaEta (400MHz, CDC13) 9.03 (I H, d, J 2.0, 2'-aryl CH), 8.71 (I H, dd, J 5.0, 1.5, 6'-aryl CH), 8.12 (I H, dt, J 8.0, 2.0, 4'-aryl CH), 7.36 (IH, dd, J 8.0, 5.0, 5'-aryl CH), 7.27 (I H, br d, J2.0, C5H4N-CONH), 5.91 (IH, br s, CONH-CH2), 4.45 (IH, dt, J 1 1.0, 5.5, CH-CO), 3.44-3.32 (2H, m, CH2NH), 2.72 (IH, dt, J 14.5, 4.5, NHCH- C 2), 2.06-1.93 (2H, m, lactam CH2), 1.70-1.54 (I H, m, lactam CH2).13C NMR: 6c (100MHz, CDC13) 171.8 (lactam C=0), 166.0 (aryl C=0), 152.5 (aryl N- CH), 148.6 (aryl N-CH), 135.3 (ortho-C(-C )), 133.4 (ipso-C), 123.6 (meta-C), 51.2 (CH-CO), 42.0 (CH2-NH), 27.3 (lactam CH2), 21.3 (lactam CH2). HRMS (+ESI) C, ,H 13N302 + H+: calcd 220.1081 ; found 220.1085. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
74% | Reference Example 1: 3-(Benzoylamino)tetrahydropyridin-2-one:; <strong>[138377-80-7]3-aminotetrahydropyridin-2-one hydrochloride</strong> (10 mmol) and K2C03 (30 mmol) were added to water (20 mL) and stirred. A solution of benzoyl chloride (10 mmol) in CH2C12 (10 mL) was added and the reaction was stirred overnight at room temperature in an inert atmosphere (using dinitrogen). The reaction was extracted with CH2C12 (3 chi 50 mL), and the combined organic layers where then dried (Na2S04) and reduced in vacuo to give a crude product which was recrystallised from CH2C12 / petroleum ether (bp 40-60 °C) to give the product (1.62 g, 74percent): Vmax/cm"1 3250 (N-H, amide), 1664, 1633, 1538 (secondary CONH, lactam), 1605, 1578, 1486 (aromatic ring), 766, 715, 704, 690 (monosubstituted benzene ring). NMR: deltaEta (400MHz, CDC13) 7.80 (2H, br d, J 7.0, ortho-H), 7.47-7.40 (1 H, m, para-U), 7.42-7.39 (1 H, m, C6H5-CONH), 7.40-7.31 (2H, m, meta-W), 6.78 (1 H, br s, CONH-CH2), 4.41 (1 H, dt, J 1 1.5, 5.5, CH-CO), 3.36-3.23 (2H, m, CH2NH), 2.59 (1 H,22P66854. WOO L Spec as Hied 8.06.1 1 dq, J 13.0, 4.5, NHCH-CH;), 1.94-1.81 (2H, m, lactam CH2), 1.64 (IH, tt, J 12.5, 8.0, NHCH-CH^).13C NMR: 5C (100MHz, CDC13) 171.9 (lactam C=0), 167.4 (aryl C=0), 134.0 (ipso- C), 131.4 (ortho-C), 128.3 (meta-C), 127.0 (para-C), 50.8 ( H-CO), 41.5 (CH2NH), 27.0 (lactam CH2), 20.9 (lactam CH2).HRMS (+ESI) Ci2H,4N202 + Na+: calcd 241.0947; found 241.0950. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
3.41 g | With triethylamine; In tetrahydrofuran; at 20℃; | To a solution of <strong>[138377-80-7]3-aminopiperidin-2-one hydrochloride</strong> (3.49 g) and triethylamine (6.20 mL) in THF (50 mL) was added di-tert-butyl bicarbonate (6.07 g) at room temperature. The reaction mixture was stirred at room temperature overnight, water was added, and the mixture was extracted with ethyl acetate. The organic layer was separated, washed with water, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give the title compound (3.41 g) .XH NMR (300 MHz, DMSO-d6) delta 1.38 (9H, s) , 1.53-2.03 (4H, m) , 3.09 (2H, brs), 3.68-3.91 (1H, m) , 6.83 (1H, d, J = 8.1 Hz), 7.48 (1H, brs) . |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
38% | General procedure: 3-Formyl-rifamycin SV (RAL)was purchased from LKT Laboratories Inc. (>98%). RAL (250.0mg, 0.34 mmol) was dissolved in 50 ml CH2Cl2 and afterthe addition of catalyst (0.025 mmol HCl/EtOH) respective mixtures wereprepared with each of the following compounds taken separately: 1-adamantylamine,1-methylpiperazine,1-(2-pyridyl)piperazine,1-(4-fluorobenzyl)piperazine,1-(2,4,6-trimethylbenzyl)piperazine, 1-bis(4-fluorophenyl)methylpiperazine, 1-(ethanesulfonyl)piperazine, 1-(methylsulfonyl)piperidin-4-amine, 4-(dimethylamino)-piperidine,1-(4-pyridyl)piperazine, 1-(2-pyrimidyl)piperazinedihydrochloride, 1,9-dimethyl-1,4,9-triazaspiro[5.5]undecanetrihydrochloride, 3,4-dihydro-2H-spiro[isoquinoline-1,4?-piperidine],n-piperidin-4-yl-methanesulfonamide,1-[3-(trifluoromethyl)pyrid-2-yl]piperazine,1-(cyclohexylmethyl)-4-piperidinamine,1,4?-bipiperidine-4-carboxylic acid dihydrochloride, (4-amino-1-piperidinyl)acetic acid dihydrochloride, 2-oxo-2-(1-piperidinyl)ethanamine,1-(2-amino-ethyl)-pyrrolidin-2-one,4-amino-1-Boc-piperidine, 3-amino-2-piperidinonehydrochloride, 1-acetyl-4-aminopiperidine hydrochloride in1 ml of CH3OH. Amines containinghydrochloride were neutralized with an equivalent amount of KOH/EtOH (0.06 mmolor 0.12 mmol or 0.18 mmol) solution. The mixtures were stirred at 40C for halfan hour and after that 3/4 of the solvent volume was distilled off. To thecooled reaction mixture (room temperature) the reductant NaBH3CN (13mg, 0.15 mmol) was added portionwise over 1 min. The reaction mixture wasstirred for one hour. Next the reaction mixture was evaporated to dryness,dissolved in 50 ml of CH2Cl2 and extracted twice with 50ml of water and brine (theses stages were omitted for reactions with1,4?-bipiperidine-4-carboxylic acid dihydrochloride,(4-amino-1-piperidinyl)acetic acid dihydrochloride). The separated organiclayer was evaporated and the synthesized derivatives of 3-formylrifamycin SV(compounds 1-23) were next purified by column chromatography with silicagel (25 cm × 1 cm, silica gel 60, 0.040-0.063 mm/230-400 mesh ASTM, Fluka) withdichloromethane/methanol (from 200:1 to 3:1) as an eluent. |
A132225 [406216-02-2]
(R)-3-Aminopiperidin-2-one hydrochloride
Similarity: 1.00
A235943 [42538-31-8]
(S)-3-Aminopiperidin-2-one hydrochloride
Similarity: 1.00
A476158 [24666-56-6]
3-Aminopiperidine-2,6-dione hydrochloride
Similarity: 0.97
A416499 [26081-03-8]
(R)-3-Aminoazepan-2-one hydrochloride
Similarity: 0.97
A132225 [406216-02-2]
(R)-3-Aminopiperidin-2-one hydrochloride
Similarity: 1.00
A235943 [42538-31-8]
(S)-3-Aminopiperidin-2-one hydrochloride
Similarity: 1.00
A476158 [24666-56-6]
3-Aminopiperidine-2,6-dione hydrochloride
Similarity: 0.97
A416499 [26081-03-8]
(R)-3-Aminoazepan-2-one hydrochloride
Similarity: 0.97
A132225 [406216-02-2]
(R)-3-Aminopiperidin-2-one hydrochloride
Similarity: 1.00
A235943 [42538-31-8]
(S)-3-Aminopiperidin-2-one hydrochloride
Similarity: 1.00
A476158 [24666-56-6]
3-Aminopiperidine-2,6-dione hydrochloride
Similarity: 0.97
A134813 [956109-56-1]
(S)-3-Amino-1-methylpiperidin-2-one hydrochloride
Similarity: 0.92